|
|
Vaccine Comparison
|
Diphtheria and Tetanus Toxoids Adsorbed |
| Vaccine Information |
- Vaccine Name: Diphtheria and Tetanus Toxoids Adsorbed
- Product Name: Diphtheria and Tetanus Toxoids Adsorbed
- Tradename: None
- Manufacturer: Sanofi Pasteur Inc
- Vaccine Ontology ID: VO_0000033
- CDC CVX code: 28
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1725), Canada
- Host Species for Licensed Use: Human
- Adjuvant:
- Preparation: The vaccine is grown in a peptone-based medium containing bovine extract. The meat used in this medium is US sourced. Both toxins are detoxified with formaldehyde. The detoxified materials are then separately purified by serial ammonium sulfate fractionation and diafiltration.
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
- Approved Age for Licensed Use: 6 weeks to 6 years of age
- Contraindication: Hypersensitivity to any component of the vaccine, including thimerosal, a mercury derivative, is a contraindication for further use of this vaccine. It is a contraindication to use this or any other related vaccine after an immediate anaphylactic reaction associated with a previous dose (FDA: Diphtheria and Tetanus Toxoids Adsorbed USP).
- Description: The primary series of vaccination for infants 6 weeks through 12 months, consists of 4 doses: administer three 0.5 mL doses intramuscularly 4 to 8 weeks apart. A reinforcing dose is given 6 to 12 months after the third injection (FDA: Diphtheria and Tetanus Toxoids Adsorbed USP).
|
| References |
FDA: Diphtheria and Tetanus Toxoids Adsorbed: FDA: Diphtheria and Tetanus Toxoids Adsorbed [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142732.pdf]
|
|
Infanrix |
| Vaccine Information |
- Vaccine Name: Infanrix
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Tradename: Infanrix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000064
- CDC CVX code: 20
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1617)
- Host Species for Licensed Use: Human
- Adjuvant:
- VO ID: VO_0000127
- Description: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: INFANRIX).
- Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract.
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store INFANRIX refrigerated between 2° and 8°C (36° and 46°F). Do not freeze.
- Approved Age for Licensed Use: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday). Because of the substantial risks of complications from pertussis disease in infants, completion of the primary series of 3 doses of vaccine early in life is strongly recommended. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older. When passive protection against tetanus or diphtheria is required, Tetanus Immune Globulin or Diphtheria Antitoxin, respectively, should be administered at separate sites (FDA: INFANRIX).
- Contraindication: Hypersensitivity to any component of the vaccine and ti should not be administered to anyone with a known previous allergic reaction associated with the vaccine (FDA: INFANRIX).
- Description: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age. INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: INFANRIX).
|
| References |
FDA: INFANRIX: FDA: INFANRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
|
|
KINRIX |
| Vaccine Information |
- Vaccine Name: KINRIX
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Tradename: KINRIX
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000067
- CDC CVX code: 130
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1617)
- Host Species for Licensed Use: Human
- Antigen: Each 0.5-mL dose is formulated to contain 25 Lf of diphtheria toxoid, 10 Lf of tetanus toxoid, 25 mcg of inactivated pertussin toxin (PT), 25 mcg of filamentous hemagglutinin (FHA), 8 mcg of pertactin (69 kiloDalton outer membrane protein), 40 D-antigen Units (DU) of Type 1 poliovirus (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett) (FDA: KINRIX).
The diphtheria, tetanus, and pertussis components of KINRIX are the same as those in INFANRIX and PEDIARIX and the poliovirus component is the same as that in PEDIARIX.
- Adjuvant:
- VO ID: VO_0000127
- Description: A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose (FDA: KINRIX).
- Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. After, they are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: KINRIX).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze.
- Approved Age for Licensed Use: A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose (FDA: KINRIX).
- Contraindication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis or poliovirus-containing vaccine, or to any component of KINRIX, including neomycin and polymyxin B, encephalopathy within 7 days of administration of a previous pertussis-containing vaccine and progressive neurologic disorders (FDA: KINRIX).
- Description: A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose (FDA: KINRIX).
|
| References |
FDA: KINRIX: FDA: KINRIX Vaccine [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241453.pdf]
|
|
Pediarix |
| Vaccine Information |
- Vaccine Name: Pediarix
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined
- Tradename: Pediarix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000082
- CDC CVX code: 110
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1617)
- Host Species for Licensed Use: Human
- Adjuvant:
- VO ID: VO_0000127
- Description: It contains diphtheria and tetanus toxoids, 3 pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin [69 kiloDalton outer membrane protein]), hepatitis B surface antigen, plus poliovirus Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett) (FDA: Pediarix).
- Allergen: yeast, neomycin,polymyxin B
- Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. The diphtheria, tetanus, and pertussis antigens are individually adsorbed onto aluminum hydroxide then diluted and combined to produce the final formulated vaccine (FDA: Pediarix).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: The vaccine should be refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
- Approved Age for Licensed Use: PEDIARIX is indicated for active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3 as a three-dose primary series in infants born of HBsAg-negative mothers, beginning as early as 6 weeks of age. PEDIARIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: Pediarix).
- Contraindication: Hypersensitivity to any component of the vaccine, including yeast, neomycin, and polymyxin B, the vaccine should also not be administered to anyone with a previous allergic reaction to a dose of the vaccine (FDA: Pediarix).
- Description: It contains diphtheria and tetanus toxoids, 3 pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin [69 kiloDalton outer membrane protein]), hepatitis B surface antigen, plus poliovirus Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett) (FDA: Pediarix).
|
| References |
FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
|
|
